Compare Autozone Inc (AZO) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Autozone Inc trades at $3,042 (market cap $50.09B), while Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M). The key difference: Autozone Inc is far larger — about 97.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | DNA | |
|---|---|---|
Market Cap | $50.09B | $515.15M |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $16.14 |
52-Week Low | $2.92K | $5.48 |
Enterprise Value | $62.46B | $617.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.
Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
